Zeit folii-Extrakt ethanolicum trocken - Resultados da pesquisa

União Europeia - romeno - EMA (European Medicines Agency)

terrosa

gedeon richter plc. - teriparatidul - osteoporoza - homeostazia de calciu - terrosa este indicat la adulți. tratamentul osteoporozei la femeile aflate în postmenopauză și la bărbații cu risc crescut de fractură. la femeile aflate în postmenopauză, sa demonstrat o reducere semnificativă a incidenței fracturilor vertebrale și non-vertebrale, dar nu a fracturilor de șold. tratamentul osteoporozei asociate cu sustinut sistemice terapia cu glucocorticoizi la femei și bărbați cu risc crescut de fractură.

União Europeia - romeno - EMA (European Medicines Agency)

tepmetko

merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

União Europeia - romeno - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teriparatidul - osteoporosis; osteoporosis, postmenopausal - homeostazia de calciu - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

União Europeia - romeno - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teriparatidul - osteoporosis; osteoporosis, postmenopausal - homeostazia de calciu - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.